Indefinite Delivery Contract 75D30122D13474

This indefinite delivery contract (IDC) award from the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC is for the procurement of up to 23 standard pediatric vaccines to support the CDC's Immunization Awardees and Vaccines for Children program. The 1-year contract, valued at a ceiling of $1,141,648,900, will provide for the delivery of a range of vaccines including dengue, DTaP, Hepatitis A and B, Hib, HPV, MMR, meningococcal, pneumococcal, rotavirus, Td, Tdap, and varicella vaccines. The contract does not have a set-aside designation and allows for a minimum of 100 doses and maximum of 13 million doses per vaccine, depending on the specific product. Performance will occur at Glaxosmithkline's facilities within the United States, and the vaccines must have a minimum 12-month shelf life. This IDC supports Section 317(j) of the Public Health Service Act and the Vaccines for Children program established under the Omnibus Budget Reconciliation Act of 1993, providing vaccines for routine pediatric immunization efforts across the 50 states and U.S. territories.